Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Shield Bio logo — Combating antibiotic resistance through innovative genomic t...

Shield Bio

Combating antibiotic resistance through innovative genomic testing to ensure treatable infections remain manageable and prevent a future health crisis.

Founded 2016 Izmir Pre-Seed Total: $12.10M Biotechnology, Health Care

General Information

Company Name Shield Bio
Founded Year 2016
Location Izmir
Industries Biotechnology, Health Care
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Shield Bio. To contact Shield Bio, visit shieldbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Shield Bio compare?

A PDF of Shield Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Shield Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Shield Bio

Shield Bio is a biotechnology startup dedicated to fighting antibiotic resistance through innovative genomic testing. The company's slogan captures its mission succinctly, emphasizing the importance of managing treatable infections to stave off a potential health crisis. With a founding year of 2016, Shield Bio operates in the biotechnology and healthcare industries, addressing a pressing global healthcare issue. The alarming prediction that antibiotic-resistant pathogens could surpass cancer in mortality rates by 2050 underscores the urgency of Shield Bio's work. The company highlights the escalating challenges posed by antibiotic resistance, pointing out the shift from simple oral antibiotics to increasingly complex and painful treatments for once manageable infections. Shield Bio emphasizes the severe health implications for patients as a result of these developments, stressing the gravity of the situation. One example cited by Shield Bio is the concerning case of gonorrhea, which has developed resistance to over ten different antibiotics, leaving only one effective treatment, which is also showing signs of resistance. The rapidly spreading antibiotic resistance, with 820,000 new infections annually in the U.S., has prompted the CDC to classify resistant gonorrhea as an urgent threat, their highest alert level. Shield Bio's solution lies in its innovative genomic testing platform, which enables STI clinics to identify antibiotic-resistant strains of gonorrhea and other pathogens in their patients. This, in turn, allows for the selection of effective antibiotics, thus curbing the spread of antibiotic resistance. The startup's focus on providing practical, immediate solutions to a critical healthcare issue demonstrates its potential to make a significant impact on public health. The company's most recent milestone was the Pre Seed Round investment on 01 April 2019, signifying a vote of confidence from investors in Shield Bio's mission and technological approach. While the specific investor details are not available, this investment underscores the recognition of Shield Bio's potential to address a pressing global health issue. As Shield Bio continues to develop and deploy its innovative genomic testing platform, it stands poised to contribute meaningfully to the fight against antibiotic resistance and the preservation of effective treatments for infectious diseases.

Business keywords: Genomic Testing, Antibiotic Resistance, STI Clinics, Pathogen Identification, Health Crisis Prevention, Innovative Medical Solutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round Undisclosed -
01 Apr 2019
Series A $8.00M 10
Valia Ventures Y Combinator Zeno Ventures
Valia Ventures, Y Combinator +8
23 May 2018
Seed Round $4.10M -
23 Feb 2017

Shield Bio Alternatives & Competitors

View All Alternatives
Shield Bio vs
First Light Diagnostics
First Light Diagnostics United States

First Light Diagnostics develops innovative diagnostic tests that enable rapid and accurate detectio...

Grant
27 employees
Biotechnology, Health Care
Shield Bio vs
Microplate Dx Limited
Microplate Dx Limited United Kingdom

Improving quality of life for patients by providing antimicrobial stewardship in a cost-effective ma...

Seed
13 employees
Biotechnology, Health Care
Shield Bio vs
Genomtec SA
Genomtec SA Poland

Molecular diagnosis everywhere, at the right time and for the right price.

Grant
26 employees
Biotechnology, Health Care
View all alternatives

FAQ About Shield Bio

Combating antibiotic resistance through innovative genomic testing to ensure treatable infections remain manageable and prevent a future health crisis.
Shield Bio was founded in 2016.
Shield Bio is headquartered in Izmir.
Shield Bio operates in Biotechnology and Health Care. Its work centres on Genomic Testing, Antibiotic Resistance, STI Clinics and Pathogen Identification.
Shield Bio has completed 3 funding rounds, raising a total of $12.10M. The latest funding stage is Pre-Seed.
Top alternatives and competitors to Shield Bio include First Light Diagnostics, Microplate Dx Limited, Genomtec SA, Gedea Biotech AB, EMPE Diagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Shield Bio and First Light Diagnostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Shield Bio, https://bouncewatch.com/company/shield-bio, updated 10 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout